Dr Daniel George is Professor of Medicine and Surgery, Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology disease-based group and is co-lead of the DCI Center for Prostate and Urologic Cancers. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 200 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and cancer disparities. He has led efforts defining the clinical benefit of VEGF receptor targeted therapy in renal cell carcinoma in both the metastatic and in the adjuvant setting. In addition, Dr George has championed studies evaluating the outcomes of novel hormonal agents by race in metastatic castration resistant prostate cancer.
Dr. George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium. He is the PI of the MaRCC and ODYSSEY registries in aRCC and Co-PI of IRONMAN, an international, multi-sponsor supported registry in advanced prostate cancer. Dr. George has served on the Conquer Cancer Foundation (CCF) Young Investigator Award Committee (Chair 2019-20), the renal cancer cadre leader for the Alliance GU Scientific Committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research and Co-editor in Chief of Clinical Advances in Hematology and Oncology.
Disclosures:
- Employment: none
- Compensation: none
- Ownership: none
- Leadership: none